TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00432796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: 5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg
Study: NCT03533881

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arom Digest Slim
Description: Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional changes
Description: Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional changes
Description: Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
Study: NCT03625310

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with TCP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with CXP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride with CPP-ACP
Study: NCT03860714

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
Study: NCT03117894

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 5 mg/ml, 35 ml
Description: Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 50 microg/ml
Description: The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 50 microg/ml
Description: The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason 4 mg
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethason 4 mg
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 1,5 g
Description: Administered preoperatively to prevent pain postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 1,5 g
Description: Administered preoperatively to prevent pain postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia, 120 mg
Description: Administered preoperatively to prevent pain postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia, 120 mg
Description: Administered preoperatively to prevent pain postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 mg
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 mg
Description: Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
Study: NCT04066296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
Study: NCT02630849

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intercostal muscle flap and pericostal no-compression suture
Description: intercostal muscle flap and pericostal no-compression suture of the intercostal space

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard suture technique of the intercostal space
Description: Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
Study: NCT01553227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilator
Description: Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
Study: NCT03440294

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: resting standard spirometry
Description: The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: resting standard spirometry
Description: The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: maximum exercise testing
Description: Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: maximum exercise testing
Description: Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
Study: NCT02678000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHW090
Description: LHW090 is orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of LHW090
Study: NCT00509379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
Study: NCT03672461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Practice Program
Description: The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Conditioning Program
Description: The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants.
Study: NCT01058486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management and Motivational Interviewing
Description: Post hospital discharge, patients will be referred (\<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts.
Study: NCT04220749

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Standard of Care: Radiation +/- Chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-Oral Surgery (TOS) + Neck Dissection
Description: Trans-Oral Surgery (TOS) + Neck Dissection (plus radiation, if required)
Study: NCT04072991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary therapy
Description: participants will undertake a four week diet as part of their IBS treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary therapy
Description: participants will undertake a four week diet as part of their IBS treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary therapy
Description: participants will undertake a four week diet as part of their IBS treatment
Study: NCT02566603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100
Description: Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Study: NCT05135884

Intervention type: BEHAVIORAL
Intervention: Standard inpatient stroke rehabilitation
Description: According to Swiss national guidelines and local protocols
Study: NCT02454075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: Gastrin receptor antagonist
Study: NCT02638675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness program
Description: All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness program
Description: All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerometer
Description: All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
Study: NCT03743129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg p.o, qd
Study: NCT01408875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low electrical myostimulation
Description: The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
Study: NCT02621047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib as per the dosage schedule mentioned in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib as per the dosage schedule mentioned in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive alectinib as per the dosage schedule mentioned in arm description.
Study: NCT03495154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parietene DS Composite Mesh
Description: All subjects enrolled will receive the Parietene DS Composite Mesh
Study: NCT01013623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: surgical resection to remove all known disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery plus 2 adjuvant doses of BCG
Description: Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
Study: NCT01671566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home based interval training
Description: The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
Study: NCT01990664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A for Astigmatism
Study: NCT01370018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alpha-1-Proteinase Inhibitor
Description: Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.
Study: NCT05047497

Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire and ventilatory function test
Description: we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups

Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire and ventilatory function test
Description: we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups

Intervention type: DIAGNOSTIC_TEST
Intervention: questionaire and ventilatory function test
Description: we assessed the arterial blood gases and the ventilatory functions and quality of life of whole three groups
Study: NCT00221702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIntron
Description: 100 mcg SC/week for 36 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intron A
Description: 3mui TIWW SC for 18 months
Study: NCT01650727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m\^2 up to a maximum dose of 14 mg/m\^2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
Study: NCT04304313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate tablets
Description: 0.1g/day for 14 days
Study: NCT03448289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLPT
Description: The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
Study: NCT00570921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablets, two-5 mg tablets a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
Study: NCT00945763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 30 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin
Description: 400 mg
Study: NCT02853305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion
Study: NCT01974934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate
Study: NCT00349388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol
Description: Asacol is given once a day versus twice or three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol
Description: Asacol is given once a day versus twice or three times a day